Earnings Call Summary | NeuroOne Medical(NMTC.US) Q2 2024 Earnings Conference
Earnings Call Summary | NeuroOne Medical(NMTC.US) Q2 2024 Earnings Conference
The following is a summary of the NeuroOne Medical Technologies Corporation (NMTC) Q2 2024 Earnings Call Transcript:
以下是NeuroOne醫療技術公司（NMTC）2024年第二季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
NeuroOne reported a significant growth in Q2 product revenue of $1.377 million, in fiscal 2024 compared to $466,000 in the same period in fiscal 2023.
The company experienced a decrease in operating expenses from $3.5 million in Q2 fiscal 2023 to $3.3 million in Q2 fiscal 2024.
Despite an improvement in net loss for Q2 fiscal 2024 compared to the same period in 2023, the net loss for the first six months of FY 2024 increased to $6.2 million.
NeuroOne報告稱，2024財年第二季度產品收入大幅增長，達到137.7萬美元，而2023財年同期爲46.6萬美元。
該公司的運營支出從2023財年第二季度的350萬美元下降到2024財年第二季度的330萬美元。
儘管與2023年同期相比，2024財年第二季度的淨虧損有所改善，但2024財年前六個月的淨虧損增加至620萬美元。
Business Progress:
業務進展：
The company made progress in commercialization and product development, with a significant increase in sales through their collaboration with Zimmer Biomet.
NeuroOne introduced the OneRF Ablation System and anticipates adding more centers in the coming quarter.
The company is also diversifying indications for their ablation generator for pain treatment and is in the midst of developing a proprietary percutaneous delivery system. They are expected to submit a new FDA application by the end of the year.
該公司在商業化和產品開發方面取得了進展，通過與Zimmer Biomet的合作，銷售額大幅增長。
NeuroOne推出了OneRF消融系統，並預計下個季度將增加更多中心。
該公司還在對用於疼痛治療的消融發生器的適應症進行多樣化，並且正在開發專有的經皮輸送系統。預計他們將在今年年底之前提交新的FDA申請。
More details: NeuroOne Medical IR
更多詳情： NeuroOne 醫療
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。